EyePoint Pharmaceuticals logo — Delivering Innovation to the Eye™

NOW HIRING!

EyePoint Pharmaceuticals

Delivering Innovation to the Eye™ NOW HIRING!

Founded 1987 190 employees Post Ipo Equity Total: $653.80M Biotechnology, Health Care +1

General Information

Company Name EyePoint Pharmaceuticals
Founded Year 1987
Founders / Decision Makers
Team member Team member Team member
Employees 190
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when EyePoint Pharmaceuticals moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert’s proven intravitreal drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA-approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 05 Dec 2023
Post-IPO Debt •••••• 1 •••• •••• 09 Mar 2022
Post-IPO Equity •••••• - 16 Nov 2021
Post-IPO Equity •••••• - 04 Feb 2021
Post-IPO Equity •••••• 1 •••• •••• 03 Jan 2021

View All 10 Funding Rounds

EyePoint Pharmaceuticals Alternatives & Competitors

EyePoint Pharmaceuticals vs
EYE-GO A/S
EYE-GO A/S Denmark

We shape the future of eye treatment.

19 employees
Health Care, Medical Devices
EyePoint Pharmaceuticals vs

La sfida che ci proponiamo è quella di rivoluzionare completamente l'approccio terapeutico nel campo...

Seed
5 employees
Health Care, Manufacturing
EyePoint Pharmaceuticals vs
Re-Vana Therapeutics
Re-Vana Therapeutics United Kingdom

To advance the quality of care for patients suffering from sight-threatening diseases.

Series A
23 employees
Health Care, Health and Wellness

FAQ About EyePoint Pharmaceuticals

Delivering Innovation to the Eye™ NOW HIRING!
EyePoint Pharmaceuticals was founded in 1987.
EyePoint Pharmaceuticals operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
EyePoint Pharmaceuticals has approximately 190 employees.
EyePoint Pharmaceuticals has completed 10 funding rounds, raising a total of $653.80M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to EyePoint Pharmaceuticals include EYE-GO A/S, MgShell S.r.l., Re-Vana Therapeutics, Kenox Pharmaceuticals, Inc, Novaliq GmbH. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
EyePoint Pharmaceuticals and EYE-GO A/S are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors EyePoint Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy